Carnitine palmitoyltransferase 1C promotes EMT-associated cisplatin resistance in non-small cell lung cancer cells by Renjie Chen, Jiahui Wang, Shuoyu Huang, Xuefeng Hu, Xinran He, Tiange Zhang, Yunhan Hu, Huijun Wei, Sihui Nian, Yushu Huang, Zhihao Wu

“…Therefore, the use of combination therapy with a CPT1C inhibitor may be a promising new avenue in lung cancer treatment.…”
Get full text

Therapeutic effects of reduced glutathione on liver function, fibrosis, and HBV DNA clearance in chronic hepatitis B patients by Qiyao Wei, Jing Zhao

“…The control group received standard entecavir treatment (0.5 mg/time, once a day, continuous treatment for 3 months), while the observation group received a combination therapy of reduced glutathione and the standard entecavir treatment. …”
Get full text

Synthetic inhibition of SREBP2 and the mevalonate pathway blocks rhabdomyosarcoma tumor growth in vitro and in vivo and promotes chemosensitization by Silvia Codenotti, Michela Asperti, Maura Poli, Luisa Lorenzi, Alberto Pietrantoni, Matteo Cassandri, Francesco Marampon, Alessandro Fanzani

“…Therefore, stimulating CHO depletion via SREBP2 and MVP inhibition may represent a viable option to improve the combination therapy protocol, especially in pAkt1-positive RMS.…”
Get full text

Identification of TUBB3 as an immunotherapy target in lung cancer by genome wide in vivo CRISPR screening by Dan Zhao, Ravindra Deshpande, Kerui Wu, Abhishek Tyagi, Sambad Sharma, Shih-Ying Wu, Fei Xing, Stacey O'Neill, Jimmy Ruiz, Feng Lyu, Kounosuke Watabe

“…Our results provide a rationale for a novel combination therapy consisting of the TUBB3 inhibition and anti-PD-1 immunotherapy for lung cancer.…”
Get full text

Immune checkpoint inhibitor‐related type 1 diabetes incidence, risk, and survival association by Fumika Kamitani, Yuichi Nishioka, Miyuki Koizumi, Hiroki Nakajima, Yukako Kurematsu, Sadanori Okada, Shinichiro Kubo, Tomoya Myojin, Tatsuya Noda, Tomoaki Imamura, Yutaka Takahashi

“…PD‐(L)1 and CTLA‐4 combination therapy was associated with an increased risk of ICI‐T1DM compared with PD‐1 monotherapy (odds ratio [OR], 2.36; 95% confidence interval [CI], 1.21–4.58; P = 0.01). …”
Get full text

Case report: PD-L1-targeted high-affinity natural killer cells and IL-15 superagonist N-803-based therapy extend overall survival of advanced metastatic pancreatic cancer patients by Tara Seery, Lennie Sender, Omid Jafari, Frank Jones, Patricia Spilman, Sandeep B. Reddy, Patrick Soon-Shiong

“…The findings here support the ongoing clinical investigations of N-803 and PD-L1 t-haNK cells in combination therapy.…”
Get full text

Pharmacoeconomics and Utilisation of Antidiabetic Medications among Type 2 Diabetes Mellitus Patients: A Longitudinal Study by Bikash Chandra Das, P Ansuman Abhisek, Deepak Choudhury, Suvendu Kumar Panda, Jayanti Prava Behera, Supriya Pradhan, Trupti Rekha Swain, Sasmita Mallick

“…Metformin was the most commonly prescribed medication, both as a standalone therapy and in combination therapy. Conclusion: Present investigation showed that rational prescribing effectively reduced blood sugar readings. …”
Get full text

To Explore the Effects of Acupuncture and Medical Treatment at Different Times on the Gastrointestinal Reaction and White Blood Cell Count of Patients with Lung Cancer Chemotherapy by Qingchun Zhao, Hui Du, Jinghao Liu, Yu Hua, Xiaoyu Niu, Jun Chen

“…Study 1 group was given tropisetron hydrochloride and acupuncture combination therapy 30 minutes before chemotherapy. Study 2 group was given tropisetron hydrochloride treatment 30 min before chemotherapy and acupuncture treatment 30 min after chemotherapy. …”
Get full text

Vinblastine resets tumor-associated macrophages toward M1 phenotype and promotes antitumor immune response by Jing Wang, Jin Wang, Yi-Na Wang, Yuan-Yuan Wang, Wen-Juan Bai, Nai-Jun Miao

“…VBL and anti-PD-1 combination therapy was then investigated in comparison with monotherapy. …”
Get full text

Hepatitis associated with immune checkpoint inhibitors-based combinations of other therapies: A real-world pharmacovigilance analysis based on the FDA adverse event reporting syste... by Zhaohui Li, Zixiang Zhou, Nan Zhang, Binhe Tian, Xiangqi Chen, Haitao Zhao, Hanping Wang

“…To date, no literature has systematically addressed the risk of hepatitis associated with the combination therapy. We conducted this pharmacovigilance analysis using the Food and Drug Administration Adverse Event Reporting System (FAERS). …”
Get full text

Unlocking the Potential of Receptor-Based Approaches in Diabetes Treatment by Mohsina Patwekar, Faheem Patwekar, J. Pavan Kumar, P. Dharani Prasad, Nazia Malik, A. Venkata Badarinath, Prashanth Parupathi, Konatham Teja Kumar Reddy, Selvaraja Elumalai, Zainul Abedeen Ab Samad

“…In the future, these medications are expected to be improved through the use of combination therapy and personalized, precision medicine. …”
Get full text

Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis by Meng Wang, Xing Huang, Tingbo Liang, Tianyu Tang, Gang Zhang, Minghao Lu, Zhengtao Hong, Junming Huang, Xiao Zhi

“…This study aimed to demonstrate the potential effect and mechanism of LTX-315 in PD-L1 inhibition-induced anti-pancreatic cancer immunity.Methods Both immunodeficient and immunocompetent mouse models were used to evaluate the therapeutic efficacy of monotherapy and combination therapy. Flow cytometry and immunohistochemistry were used to assess the immune microenvironment. …”
Get full text

Efficacy and safety of sequential therapy for primary osteoporosis with bone formation promoters followed by bone resorption inhibitors: a meta-analysis by Yuxin Liu, Xin Liu, Yuefeng Wu, Tao Luo

“…Pooled analysis showed that the intervention group (bone formation promoters followed by bone resorption inhibitors) increased BMD at the spine (SMD:1.64; 95% CI: 0.97, 2.31; P < 0.00001; I2 = 99%), femoral neck (SMD: 0.57; 95% CI: 0.16, 0.99; P = 0.007; I2 = 96%), and total hip (SMD: 0.82; 95% CI: 0.16, 1.48; P = 0.02; I2 = 97%) compared with the comparator group (monotherapy or combination therapy using two drugs)for postmenopausal osteoporosis patient; however, there was no statistically significant difference observed in the increase of BMD at the 1/3 distal radius comparing the intervention group and comparator group (SMD: -0.25; 95% CI: -1.49, 0.99; P = 0.069; I2 = 92%). …”
Get full text

Simultaneous Quantification of Pioglitazone and Omarigliptin in Rat Plasma by UHPLC-MS/MS and Its Application to Pharmacokinetic Study after Coadministration of the Two Drugs by Lin Wang, Jiaxi Wang, Chao Lin, Furong Wang, Xiangping Li, Wanhui Liu

“…Combination therapy is a common approach for clinical treatment of type 2 diabetes mellitus, especially for patients with poor monotherapy. …”
Get full text

From chaos to order: optimizing fecal microbiota transplantation for enhanced immune checkpoint inhibitors efficacy by Anqi Lin, Aimin Jiang, Lihaoyun Huang, Yu Li, Chunyanx Zhang, Lingxuan Zhu, Weiming Mou, Zaoqu Liu, Jian Zhang, Quan Cheng, Ting Wei, Peng Luo

“…This comprehensive review seeks to guide future research endeavors and clinical applications of FMT-ICIs combination therapy, with the potential to improve cancer patient outcomes while ensuring both safety and efficacy. …”
Get full text

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double‐Blind, Parallel‐Group, R... by Hongjie Chi, Xin Zhang, Shumei Ma, Gang Pan, Xiaojuan Lian, Yan Chen, Haotian Pei, Zichen Liu, Xiangmin Lin

“…Abstract This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in patients with mild‐to‐moderate essential hypertension. …”
Get full text

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer by Benchao Zheng, Hongbo Wang, Shiyi Zhai, Jiangsheng Li, Kuangda Lu

“…Herein, we constructed a multifunctional nanoplatform that enables mitochondria-targeted photothermal-chemodynamic combination therapy by conjugating indocyanine green-thiol (ICG-SH) and mercaptoethyl-triphenylphosphonium (TPP-SH) onto polyvinyl pyrrolidone (PVP)-coated gold-copper nanoparticles (AIT). …”
Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

“…Abstract Purpose Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
Get full text

Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered by Pengfei Chen, Kun Li, Jinwei Chen, He Hei, Jiaxin Geng, Nannan Huang, Mengyu Lei, Huijie Jia, Jianzhuang Ren, Chenwang Jin

“…In this study, an H22 subcutaneous tumor mouse model was used, with animals divided into five groups for treatment with a blank control, a blank Salmonella plasmid, RFA alone, siRNA-PD-L1-endostatin, or a combination of RFA and siRNA-PD-L1-endostatin. The combination therapy significantly reduced tumor growth, angiogenesis, and PD-L1/VEGF expression in tumor tissues post-RFA. …”
Get full text

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells agains... by Weiting Liao, Ge Gao, Xia He, Pei Shu, Qizhi Ma, Benxia Zhang, Diyuan Qin, Yongsheng Wang

“…Backgrounds Chimeric antigen receptor (CAR)-modified T cells (CAR-T) are limited in solid tumors due to the hostile tumor microenvironment (TME). Combination therapy could be a promising approach to overcome this obstacle. …”
Get full text